Real-time stock price, financial statements, consensus target price, insider trading, and technical analysis for CTC Bio Inc. (060590:KRX), powered by AI.
CTC Bio Inc. is currently trading at ₩3,260. View real-time AI analysis on Alpha Lenz.
View the latest insider trading data for CTC Bio Inc. on Alpha Lenz.
CTC Bio Inc.'s P/E ratio is 24.3.
“CTC Bio Inc. trades at a P/E of 24.3 (fair value) with modest ROE of 4.6%.”
Ask for details →CTC Bio Inc. is a biotechnology and pharmaceutical company specializing in the development of health-related products. Its primary function is to advance healthcare solutions through innovative research and development in biotechnology and pharmaceuticals. CTC Bio Inc. focuses on creating products that address diverse medical needs, including dietary supplements, pharmaceuticals, and bio-healthcare products. The company's influence is significant in sectors such as healthcare, nutrition, and pharmaceuticals, where it plays a role in improving human health and wellness. CTC Bio's operations contribute to the growing field of biotechnology, reflecting the increasing demand for advanced medical and health solutions. Within the financial market, CTC Bio Inc. holds an essential position by pushing forward the boundaries of medical science and responding to modern healthcare challenges. The company is noted for its commitment to quality and effective health solutions, positioning itself as a key player in the South Korean and global biotechnology landscape.
“CTC Bio Inc. trades at a P/E of 24.3 (fair value) with modest ROE of 4.6%.”
Ask for details →CTC Bio Inc. (ticker: 060590) is a company listed on KRX in the Healthcare sector (Biotechnology). It has approximately 248 employees. Market cap is $78.8B.
The current price is ₩3,260 with a P/E ratio of 24.33x and P/B of 1.08x.
ROE is 4.55% and operating margin is 5.05%. Annual revenue is $123.8B.